Springer Nature, the German-British journal publisher, announced plans on Thursday to raise €200 million ($221 million) through an initial public offering (IPO) in Frankfurt. This would mark the first major European listing in the second half of 2024.

Springer Nature's German IPO : IPO Structure and Goals

The company plans to raise €200 million via a capital increase and the sale of existing shares held by British private equity firm BC Partners, one of its owners. Springer Nature’s IPO will take place on the regulated market — prime standard — of the Frankfurt Stock Exchange, with plans to complete the listing by December 2024, subject to market conditions.

Holtzbrinck Publishing Group, which owns 53% of the company, will not sell any of its shares during the IPO, while BC Partners, which holds 47%, will sell part of its stake.

Financial Performance and Dividend Plan

Springer Nature reported revenues of €1.85 billion in 2023, an increase from €1.82 billion in 2022. The company, which specializes in research, health, and education publishing, also plans to pay a €25 million dividend for the year ending December 2024. After its IPO, Springer Nature aims to pay an annual dividend of 50% of its adjusted net income.

Springer Nature's German IPO : Market Impact and Advisors

The IPO is expected to boost Europe's capital markets, which have seen fewer listings in 2024. The transaction follows other high-profile flotations such as Swiss skincare firm Galderma’s $2.4 billion IPO and CVC Capital Partners PLC’s €2 billion listing.

Deutsche Bank, JP Morgan SE, and Morgan Stanley Europe SE are serving as joint global coordinators for the IPO, with additional support from BNP Paribas, Commerzbank, Goldman Sachs, and UniCredit as joint bookrunners.